Zhang et al., 2013 - Google Patents
Multiple antigen-presenting system (MAPS) to induce comprehensive B-and T-cell immunityZhang et al., 2013
View HTML- Document ID
- 9417449596057396809
- Author
- Zhang F
- Lu Y
- Malley R
- Publication year
- Publication venue
- Proceedings of the National Academy of Sciences
External Links
Snippet
Vaccines are among the most effective approaches to prevent and control many infectious diseases. Because of safety and reproducibility concerns, whole-cell vaccines (WCVs), made from live or killed microorganisms and including hundreds of antigenic components …
- 210000001744 T-Lymphocytes 0 title abstract description 26
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Multiple antigen-presenting system (MAPS) to induce comprehensive B-and T-cell immunity | |
Micoli et al. | Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella | |
Bagnoli et al. | Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus | |
Chen | Current advances and challenges in the development of Acinetobacter vaccines | |
Thiem et al. | The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines | |
Svennerholm et al. | Recent progress toward an enterotoxigenic Escherichia coli vaccine | |
Malley et al. | Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide | |
Rivera-Hernandez et al. | Vaccine-induced Th1-type response protects against invasive group A Streptococcus infection in the absence of opsonizing antibodies | |
Yeaman et al. | Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection | |
Al-Mariri et al. | Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp | |
Moffitt et al. | Rationale and prospects for novel pneumococcal vaccines | |
Cross | Anti-endotoxin vaccines: back to the future | |
Adler et al. | Pneumococcal capsular polysaccharide immunity in the elderly | |
Segal et al. | Vaccines against bacterial meningitis | |
Lijek et al. | Protection from the acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenase | |
Stokes et al. | Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis | |
Chan et al. | A novel, multiple-antigen pneumococcal vaccine protects against lethal Streptococcus pneumoniae challenge | |
Thanawastien et al. | Conjugate-like immunogens produced as protein capsular matrix vaccines | |
Gallorini et al. | Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides | |
Tournier et al. | Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis | |
Olafsdottir et al. | Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice | |
Wolf et al. | Intranasal immunization with acellular pertussis vaccines results in long-term immunity to Bordetella pertussis in mice | |
Hozbor | Outer membrane vesicles: an attractive candidate for pertussis vaccines | |
Cui et al. | Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates | |
Moshiri et al. | Outer membrane vesicle: a macromolecule with multifunctional activity |